Immucell Corp

ICCCNASDAQ • USD
11.42 USD
↗ 0.67 (6.23%)AT CLOSE (03:59 PM EST)
11.20
↘ 0.22 (1.93%)
POST MARKET (AS OF 07:30 PM EST)
Post Market
AS OF 07:30 PM EST
11.20
↘ 0.22 (1.93%)
🔴Market: CLOSED

Immucell Corp (ICCC) trades at $11.25 per share. Both sides of the analysis agree: technicals flash "Strong Buy" and fundamentals confirm with a "Buy" reading. This is driven by a robust Altman Z-Score, a bullish Golden Cross on the moving averages and bullish moving average alignment. On valuation, ICCC trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 16, 2026.

Open?$10.75
High?$11.66
Low?$10.75
Prev. Close?$10.75
Volume?101.7K
Avg. Volume?11.9K
VWAP?$11.23
Rel. Volume?8.52x
Bid / Ask
Bid?$9.60 × 1.0K
Ask?$12.00 × 100
Spread?$2.40
Midpoint?$10.80
Valuation & Ratios
Market Cap?103.8M
Shares Out?9.1M
Float?6.0M
Float %?66.3%
P/E Ratio?55.24
P/B Ratio?3.17
EPS?$0.21
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
ImmuCell Corp is an animal health biologics company focused on the development, manufacture, and commercialization of products intended to improve the survivability, health, and long-term performance of neonatal dairy and beef calves. Its product, First Defense, utilizes hyperimmunized bovine colostrum to provide pathogen-specific antibodies and other bioactive components. First Defense is designed to provide Immediate Immunity through orally delivered antibodies against the principal viral and bacterial causes of neonatal calf diarrhea (scours), including Escherichia coli (E.coli), bovine coronavirus, and bovine rotavirus. It has two operating segments: Scours and Mastitis. It derives the majority of the revenue from the Scours segment that consists of the First Defense product line.
Employees
73
Market Cap
97.7M
Industry
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Listed
1987-07-08
Address
56 EVERGREEN DR
PORTLAND, ME 04103
Phone: (207) 878-2770
Technical OutlookStrong Buy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+3/3)
Medium-Term (Wave)?▲ Bullish(+3/3)
Short-Term (Ripple)?▲ Bullish(+2/3)
MA Alignment?Golden Alignment
Full Technical Analysis →
Fundamental OutlookBuy
Strong SellNeutralStrong Buy
F-Score?
77
Z-Score?
99
Momentum?
33
Short Sent.?
94
Piotroski F-Score?6/9Mixed
Altman Z-Score?5.24Safe
Confidence?52%Low
Full Fundamental Analysis →
Short InterestLow
Short % of Float?0.25%Low
Short Interest?14.7K
Days to Cover?2.8
Free Float6.0M
Avg Daily Volume5.3K
Settlement Date2026-10-30
Financial Health
Current Ratio?4.61Strong
Quick Ratio?2.50Strong
Cash Ratio?1.69Strong
Debt/Equity?0.24Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
Peers
100
S&P
10
55.2PRICEY▾
P/B?
Peers
100
S&P
53
3.17FAIR▾
P/S?
Peers
100
S&P
49
3.13FAIR▾
P/FCF?
Peers
100
S&P
58
19.2CHEAP▾
EV/EBITDA?
Peers
100
S&P
51
14.9FAIR▾
EV/Sales?
Peers
100
S&P
59
3.13FAIR▾
Returns & Efficiency
ROE?
Peers
50
S&P
20
5.7%FAIR▾
ROA?
Peers
50
S&P
36
3.9%FAIR▾
Cash Flow & Enterprise
FCF?$5.4M
Enterprise Value?$103.8M
Fundamentals ratios updated end of day